Brief: Epivax Says Chugai Pharmaceutical Renewed License To Co's Toolkit For Immunogenicity Assessment
22/10/2019 21:52
Oct 22 (Reuters) - EpiVax Inc:
* EPIVAX - CHUGAI PHARMACEUTICAL RENEWS LICENSE TO CO'S
ISPRI IN
SILICO TOOLKIT FOR IMMUNOGENICITY ASSESSMENT
* EPIVAX - 3-YEAR EXTENSION WITH CHUGAI WILL CONTINUE COS'
BUSINESS RELATIONSHIP INTO 2022
Source text for Eikon: ID:nPn6M5t6Ha
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)